What's New in Allergic Itch

The speaker discusses recent developments in the field of allergic itch, particularly focusing on off-label uses of medications such as Montelukast and gabapentin, and highlights new approaches to managing food allergies with the approval of omalizumab. Montelukast, used off-label for urticaria, now has an FDA black box warning due to potential mental health side effects. Gabapentin and pregabalin are frequently used for treating pruritus, yet they carry risks, especially when combined with other CNS suppressive drugs. The recent approval of omalizumab for multiple food allergies has generated excitement, given the increasing prevalence of food allergies among both children and adults. Clinical trials have shown promising results for its effectiveness in desensitizing patients to allergens, although there is concern about patients misjudging their tolerance. The speaker encourages screening for anaphylaxis in atopic patients, as food allergies are common in this group, and stresses the importance of patient education on carrying epinephrine auto-injectors. Lastly, the discussion touches on the impact of climate change on allergic diseases, promoting environmental awareness within healthcare practices and encouraging future progress in treatment methods. Overall, there's optimism for advancements in managing allergic conditions and improving patient quality of life.